Efficacy Data on Covid-19 Vaccine Could Be Out by Thanksgiving, Says Moderna CEO

The video discusses the phase three trial of a vaccine involving 30,000 participants, highlighting the importance of a large safety database and geographical diversity in trial sites. The timeline aims for efficacy data by Thanksgiving, contingent on various factors. The FDA's review process for potential emergency use approval for high-risk groups is also covered.

What is the primary purpose of having 30,000 participants in the phase three trial?

• To ensure a diverse age group

• To create a large safety database

• To reduce the cost of the trial

• To test multiple vaccines simultaneously

Why is it important to conduct the trial across various locations in the US?

• To test different vaccine formulations

• To minimize travel costs

• To ensure a diverse participant pool

• To capture data from different geographical areas

By when is the efficacy data expected to be available, assuming everything goes as planned?

• Easter

• Thanksgiving

• New Year

• Christmas

Who decides whether to grant emergency use approval for the vaccine?

• The World Health Organization

• The Centers for Disease Control and Prevention

• The vaccine manufacturer

• The FDA

Which groups might receive the vaccine under emergency use approval?

• All adults over 18

• Children and teenagers

• High-risk individuals like healthcare workers and the elderly

• Only those who volunteer for the trial